AEON Biopharma(AEON) - 2025 Q1 - Quarterly Results

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update – Appointed Rob Bancroft as the Company's President and Chief Executive Officer; Mr. Bancroft also joined AEON's Board of Directors – IRVINE, Calif., May 14, 2025 – AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced its financial results for the first quar ...